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Objective: To compare clinical outcome of paclitaxel eluting stents (PES) versus sirolimus eluting stents
(SES) for the treatment of acute ST elevation myocardial infarction.
Design and patients: The first 136 consecutive patients treated exclusively with PES in the setting of
primary percutaneous coronary intervention for acute myocardial infarction in this single centre registry
were prospectively clinically assessed at 30 days and one year. They were compared with 186 consecutive
patients treated exclusively with SES in the preceding period.
Setting: Academic tertiary referral centre.
Results: At 30 days, the rate of all cause mortality and reinfarction was similar between groups (6.5% v
6.6% for SES and PES, respectively, p = 1.0). A significant difference in target vessel revascularisation
(TVR) was seen in favour of SES (1.1% v 5.1% for PES, p = 0.04). This was driven by stent thrombosis
(n = 4), especially in the bifurcation stenting (n = 2). At one year, no significant differences were seen
between groups, with no late thrombosis and 1.5% in-stent restenosis (needing TVR) in PES versus no
reinterventions in SES (p = 0.2). One year survival free of major adverse cardiac events (MACE) was
90.2% for SES and 85% for PES (p = 0.16).
Conclusions: No significant differences were seen in MACE-free survival at one year between SES and PES
for the treatment of acute myocardial infarction with very low rates of reintervention for restenosis.
Bifurcation stenting in acute myocardial infarction should, if possible, be avoided because of the increased
risk of stent thrombosis.
T
he efficacy of drug eluting stents to treat coronary artery
stenosis in stable patients has been proved in recent trials
with single digit restenosis rates for non-complex
lesions.1–4
The potential risk of higher thrombogenicity, however, has
led to prolonged antiplatelet treatment and cautious use of
these stents for acute coronary syndromes. We have recently
shown that the use of sirolimus eluting stents (SES) for acute
myocardial infarction is safe and not associated with higher
thrombogenicity.5 The safety and efficacy of paclitaxel eluting
stents (PES) in this setting has not been reported yet.
A recent meta-analysis clearly showed the benefit of
primary percutaneous coronary intervention (PCI) over
administration of thrombolytics for the treatment of acute
myocardial infarction.6 The superiority of (bare metal)
stenting over balloon angioplasty has been well documented
in the setting of acute myocardial infarction.7
We report the one year clinical outcome of a consecutive
patient cohort treated solely with PES in the setting of
primary PCI for acute ST elevation myocardial infarction. We
compared their outcome with that of an earlier published
patient population treated with SES.
METHODS
Patients
Since 16 February 2003, PES (Taxus; Boston Scientific,
Galway, Ireland) has been implemented in our hospital as
the default stent for all patients. Data were collected for the
T-SEARCH (Taxus stent evaluated at Rotterdam Cardiology
Hospital) registry.8 This is a prospective single centre registry
set up with the main purpose of evaluating the safety and
efficacy of PES implantation for patients treated in daily
practice. Until September 2003, 136 consecutive patients
received exclusively PES in the setting of primary PCI for
acute myocardial infarction. All patients were enrolled in the
analysis including patients in cardiogenic shock (defined as
persistent systolic blood pressure , 90 mm Hg or the need
for vasopressors or intra-aortic balloon pumping required to
maintain blood pressure . 90 mm Hg with evidence of end
organ failure and increased left ventricular filling pressures).
Patients who underwent rescue PCI after failed thrombolysis
were not included in this study.
One year clinical outcome was compared with the one year
data from the first 186 patients treated exclusively with SES
in the setting of primary PCI for acute myocardial infarction
between April 2002 and January 2003, when SES was the
default stent in our centre.5
This study protocol was approved by the local ethics
committee, and written informed consent was obtained from
every patient.
Treatment strategy and definitions
The interventional strategy and use of glycoprotein IIb/IIIa
inhibitors was left entirely to the discretion of the operator.
Clopidogrel was recommended for six months, in addition to
Abbreviations: ASA, acetylsalicylic acid; MACE, major adverse
cardiac events; PCI, percutaneous coronary intervention; PES, paclitaxel
eluting stents; SES, sirolimus eluting stents; T-SEARCH, Taxus stent
evaluated at Rotterdam Cardiology Hospital; TIMI, thrombolysis in
myocardial infarction; TVR, target vessel revascularisation
1176
www.heartjnl.com
 on 4 October 2006 heart.bmjjournals.comDownloaded from 
lifelong acetylsalicylic acid (ASA) 80 mg. The loading dose of
300 mg clopidogrel was given before the intervention. If the
patient was not taking ASA, 250 mg of intravenous ASA was
given at the start of the procedure.
The occurrence of major adverse cardiac events (MACE)
was evaluated at one year. MACE were all cause mortality,
non-fatal myocardial infarction, and target lesion revascular-
isation or target vessel revascularisation (TVR).
Reinfarction was defined as new symptoms or new ECG
changes in association with an increase in creatine kinase MB
fraction concentrations of 1.5 times the previous value if
measured within 48 hours or . 3 times the upper normal limit
if measured. 48 hours after the index infarction. Target lesion
revascularisation was defined as a repeat intervention (surgical
or percutaneous) to treat a luminal stenosis within the stent or
in the 5 mm distal or proximal segments adjacent to the stent.
TVR was defined as a repeat intervention driven by any lesion
located in the same epicardial vessel treated at the index
procedure. Thrombotic stent occlusion was angiographically
documented as a complete occlusion (TIMI (thrombolysis in
myocardial infarction) flow grade 0 or 1) or a flow limiting
thrombus (with TIMI flow 1 or 2) of a previously successfully
treated artery.
Follow up
All patients were clinically followed up. Repeat angiography
was clinically driven by symptoms or signs of ischaemia.
Information about in-hospital outcomes was obtained from
our institutional electronic clinical database and by review of
the hospital records for patients discharged to referring
hospitals (patients were referred from 14 local hospitals).
Postdischarge survival status was obtained from the muni-
cipal civil registries at one, six, and 12 months. Data on all
repeat interventions (surgical and percutaneous) and repeat
Table 1 Baseline characteristics
SES (n = 186) PES (n = 136) p Value
Men 74.7% 83.8% 0.06
Age (years) 59.7 (11.7) 59.2 (12.1) 0.7
Diabetes 10.8% 3.7% 0.02
Current smoking 45.7% 44.9% 0.9
Hypercholesterolaemia 33.9% 30.1% 0.5
Hypertension 24.2% 20.6% 0.5
Previous myocardial infarction 14.4% 10.6% 0.4
Previous PCI 6.5% 5.9% 1.0
Previous CABG 1.6% 2.2% 0.7
Coronary artery disease 0.9
1 vessel 54.8% 52.2%
2 vessel 27.4% 28.7%
3 vessel 17.7% 19.1%
Cardiogenic shock 13.4% 11.8% 0.7
Time from symptom onset to PCI (hours) 3.2 (1.9) 3.1 (2.4) 0.7
Infarct related vessel 0.6
LAD 52.7% 51.5%
LCx 8.2% 8.8%
RCA 37.4% 36.0%
Left main stem 1.6% 2.2%
Saphenous vein graft 0% 1.5%
Bifurcation lesion 8.6% 9.6% 0.8
Number of vessels treated 1.0
1 84.9% 86.0%
.1 15.1% 14.0%
TIMI flow baseline grade 0.4
0–1 73.1% 78.7%
2 16.5% 11.0%
3 10.4% 10.3%
TIMI flow final grade 0.7
0–1 2.1% 2.2%
2 14.8% 11.8%
3 83.0% 86.0%
Number of stents 1.9 (1.2) 1.8 (1.1) 0.4
Total stented length (mm) 34.7 (23.5) 35.9 (22.9) 0.6
Mean nominal stent diameter (mm) 2.89 (0.16) 3.11 (0.33) ,0.001
Glycoprotein IIb/IIIa inhibitor 36.6% 55.1% 0.001
Peak CK (IU) 3126 (3126) 3234 (2567) 0.8
Peak CK-MB (IU) 296 (255) 359 (330) 0.2
Data are mean (SD) or percentage.
CABG, coronary artery bypass graft; CK, creating kinase; LAD, left anterior descending coronary artery; LCx, left
circumflex artery; PCI, percutaneous coronary intervention; PES, paclitaxel eluting stents; RCA, right coronary
artery; SES, sirolimus eluting stents; TIMI, thrombolysis in myocardial infarction.
Table 2 Major adverse cardiac events at 30 days and
one year
SES
(n = 186)
PES
(n = 136) p Value*
0–1 month
Death 5.9% 5.9% 1.0
Death or re-MI 6.5% 6.6% 1.0
TLR 1.1% 4.4% 0.07
TVR 1.1% 5.1% 0.04
Death, re-MI, or TVR 7.5% 10.3% 0.4
Stent thrombosis 0% 2.9% 0.03
0–12 months
Death 8.1% 8.1% 1.0
Death or re-MI 9.2% 10.3% 0.7
TLR 1.1% 5.9% 0.02
TVR 1.1% 6.6% 0.01
Death, re-MI, or TVR 9.7% 14.7% 0.22
Stent thrombosis 0% 2.9% 0.03
*By Fisher’s exact test.
re-MI, reinfarction; TLR, target lesion revascularisation; TVR, target vessel
revascularisation.
Paclitaxel eluting stents in myocardial infarction 1177
www.heartjnl.com
 on 4 October 2006 heart.bmjjournals.comDownloaded from 
hospitalisations were prospectively collected during follow
up. Questionnaires regarding anginal status and medication
use were sent to all living patients at six and 12 months.
Referring physicians and institutions were contacted for
additional information if required.
Statistical analysis
Continuous variables are presented as mean (SD) and were
compared by Student’s unpaired t test. Categorical variables
are presented as counts and percentages and compared by
Fisher’s exact test. All statistical tests were two tailed. The
cumulative incidence of adverse events was estimated
according to the Kaplan-Meier method and compared by
the log rank test. Cox proportional hazards survival models
were used to assess risk reduction. Multivariate analyses
were performed to identify independent predictors of long
term MACE. Significant baseline and procedural character-
istics at univariate analysis (tested variables: age, diabetes,
cardiogenic shock, multivessel disease, left main stem as the
infarct related artery, postprocedural TIMI flow, bifurcation
treatment, multivessel treatment, and duration of pain), sex,
and stent type were tested for their multivariate predictive
value. The first model was built by backwards stepwise
variable selection with the exit criteria set at the p = 0.1
level; the final model was built by forcing stent type together
with all significant predictors.
RESULTS
In total 136 patients were treated with PES only in the setting
of primary PCI for acute myocardial infarction in the study
period. These patients were compared with 186 patients
treated with SES for the same indication in the period before
our centre switched to PES as the default strategy. Follow up
of the 186 patients with SES from our earlier report5 was
extended from 300 days to one year for the comparison. At
one year after the procedure, follow up was available for
98.4% of patients.
Table 1 lists baseline characteristics. Fewer PES patients
had diabetes (3.7% v 10.8%, p = 0.02). PES patients had a
larger nominal stent size (3.11 v 2.89 mm, p , 0.001) and a
higher percentage of periprocedural glycoprotein IIb/IIIa
inhibitor use (55.1% v 36.6%, p = 0.001). Despite inclusion
of consecutive patients in both SES and PES groups, the
prevalence of diabetes differed significantly. This does not
reflect selection bias. The smaller nominal stent size in the
SES group reflects the unavailability of SES . 3.0 mm at the
time of the study.
MACE were analysed at one month and one year. Table 2
shows the results. No significant difference was seen in death
and death or reinfarction between the two groups either in
the first month or at late follow up. However, a significant
difference in TVR was seen in favour of SES, which was
already apparent at 30 days driven by stent thrombosis.
Six of seven patients with TVR within 30 days in the PES
group received target lesion reintervention. Of these, four
interventions were necessary because of subacute stent
thrombosis (table 3). Only one of these patients had been
treated with periprocedural glycoprotein IIb/IIIa inhibitor
during the index procedure.
Two of four stent thromboses were in patients treated with
bifurcation lesions (one patient with crush bifurcation
stenting without kissing balloon postdilatation but with
periprocedural glycoprotein IIb/IIIa inhibitor and one patient
with T stent bifurcation stenting without kissing balloon
postdilatation and without glycoprotein IIb/IIIa inhibitor).
The two remaining cases were caused by stent under-
expansion, diagnosed at reintervention.
Table 3 Characteristics of individual cases of PES stent thrombosis
Patient number
1 2 3 4
Patient age (years) 59 50 52 47
Sex Male Male Female Female
Time to thrombosis 1 hour 4 days 4 days 6 days
Lesion type (AHA classification) B2 B2 C C
Number of stents 1 1 2 2
Total stent length (mm) 28 24 44 36
Smallest stent diameter (mm) 3.0 3.5 2.25 2.5
Treated vessel RCA LAD LCx, OMCx LAD, 1st diagonal
Bifurcation stenting No No T stent Crush
Kissing balloon postdilatation NA NA No No
Abciximab during index procedure No No No Yes
AHA, American Heart Association; NA, not applicable; OMCx, obtuse marginal branch of the left circumflex
artery.
Table 4 Bifurcation lesions: treatment strategy
SES (n = 16) PES (n = 13) p Value
Main branch stent only 3 (18.8%) 3 (23.1%) 0.4*
Crush 2 (12.5%) 4 (30.8%)
Culotte 0 1 (7.7%)
T stent 9 (56.3%) 3 (23.1%)
V stent 2 (12.5%) 2 (15.4%)
Final kissing balloon 6 (42.9%) 8 (61.5%) 0.3
*Across all strategies by x2 test.
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Figure 1 Survival free of death, reinfarction, or target vessel
revascularisation of patients who received a sirolimus eluting stent (SES)
versus a paclitaxel eluting stent (PES) by Kaplan-Meier estimate.
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The bifurcation stenting percentage was not significantly
different between groups (8.6% v 9.6% for SES and PES,
respectively, p = 0.8). Although across all strategies no
significant difference was found in bifurcation lesion treat-
ment between SES and PES patients, a trend was seen
towards more crush stenting and less T stenting in PES
patients (table 4).
MACE-free survival at 12 months was 90.2% for SES and
85% for PES patients (p = 0.16, by Kaplan-Meier estimate)
(fig 1).
On multivariate analysis, stent type was not an indepen-
dent predictor of MACE at one year and, when forced into the
model of significant predictors, remained non-significant
(p = 0.14) (table 5). However, independent predictors were
TIMI flow 0 or 1 (hazard ratio (HR) 10.2), cardiogenic shock
(HR 4.4), and diabetes mellitus (HR 4.8).
DISCUSSION
The main finding of this sequential registry report is that
patients treated with drug eluting stents for acute myocardial
infarction have a very low rate of repeat revascularisation for
restenosis at one year’s follow up.
Although no significant difference in MACE at one year
was found between the two drug eluting stents, a trend to
worse outcome was seen in the patients treated with PES,
despite more favourable baseline characteristics such as less
diabetes, higher use of glycoprotein IIb/IIIa inhibitors, and
larger nominal stent diameter.
Short term follow up
The largest difference between the groups was TVR in the
first 30 days. These were mainly driven by stent thrombosis.
With respect to these observations of two of 13 stent
thromboses in bifurcation lesions and two of 123 in non-
bifurcation lesions, it seems prudent to try to avoid using two
stents for bifurcation treatment in acute myocardial infarc-
tion. If this is unavoidable, the risk for stent thrombosis may
be reduced by kissing balloon postdilatation and periproce-
dural glycoprotein IIb/IIIa inhibitor. In a separate study of
2500 patients we confirmed that bifurcation stenting in acute
myocardial infarction was a significant predictor of stent
thrombosis and conferred a 13-fold increase in risk.9 It may
be advisable to keep procedures short and simple for patients
undergoing angioplasty for acute myocardial infarction.
The overall rate of stent thrombosis was 1.2% (four of 322)
for drug eluting stent use in acute myocardial infarction. This
is comparable with the stent thrombosis rate with bare
stents9 10 and drug eluting stents9 used in the treatment of
patients for stable coronary lesions.
Long term follow up
Between 30 days and one year two patients treated with PES
were referred for TVR, both for in-stent restenosis (1.5%),
compared with no additional interventions for the SES
patients.
No late stent thrombosis was diagnosed in either group. In
this study, the risk for late stent thrombosis after stopping
clopidogrel, which was prescribed for six months for the PES
and 3–6 months for the SES group, does not seem to be
increased for treatment of patients with acute coronary
syndromes with drug eluting stents. It is important that, to
address this potential problem conclusively, larger studies
specifically looking at this end point be performed.
Furthermore, until more is known, complete cessation of
antiplatelets should be avoided if possible to avoid the risk of
late thrombosis, as McFadden et al11 recently pointed out.
Early and one year mortality was identical in both groups
(5.9% at 30 days and 8.1% at one year for SES and PES). This
is very comparable with earlier studies6 despite the presence
of cardiogenic shock in 12% of patients and multivessel
disease in almost half. As shown before, mortality is not
changed by the use of drug eluting stents.5 Their benefit is
reduction of reintervention as in elective PCI.
The recommendations in the most recent National
Institute for Health and Clinical Excellence guidelines
explicitly exclude acute myocardial infarction and lesions
with visible thrombus as indications for use of drug eluting
stents.12 Our results are reassuring and do not indicate that
patients with acute myocardial infarction should be denied
the benefit of the very low reintervention rates with drug
eluting stents.
Conclusions
The use of PES for the treatment of acute myocardial
infarction seems safe. No significant differences were seen
with the results of SES at one year’s follow up with a very low
rate of reintervention for restenosis. However, a trend
towards more early reinterventions was evident, mainly due
to stent thrombosis. Bifurcation stenting should be avoided
in the setting of primary PCI, if possible.
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Diabetic keto-acidosis and hyperkalaemia induced pseudo-myocardial infarction
S
T segment elevation on ECG has other
causes apart from myocardial infarction
(MI) and in the thrombolytic treatment
era, this may expose the patient to unneces-
sary drug treatment or invasive procedures
that have the potential risk of complications.
A 30 year old insulin dependent diabetic
man was treated for severe diabetic keto-
acidosis. He was a smoker with a 15 year
history of diabetes mellitus. His potassium
on admission was 6.5 mmol/l and his ECG
showed tall, peaked T wave (panel A). Eight
hours following admission, ST segment
elevation was noted on the monitor and an
inferolateral acute MI pattern (panel B) was
confirmed by ECG. The patient had no chest
pain but was thrombolysed with tenecte-
plase with no resolution of his ST segment
elevation; his potassium at the time of the ST
elevation was 6.9 mmol/l. He was referred to
our centre for coronary angiography, which
surprisingly was entirely normal but with
poor left ventricular function. Cardiac tropo-
nin T was raised at 2.54 mg/l and the ST
segment elevation was improving gradually.
He was treated medically and made a good
recovery and was discharged home seven
days later.
Hyperkalaemia may produce multiple ECG
abnormalities, including ST segment eleva-
tion and pseudoinfarct pattern with resolu-
tion of these abnormalities on correcting the
hyperkalaemia. When faced with a patient
with hyperkalaemia, ST segment elevation
may pose a diagnostic and management
dilemma regarding the use of thrombolysis.
We suggest that while measures are under-
taken to correct the metabolic derangement,
an immediate referral for coronary angio-
graphy should be the first approach.
Alternatively, bedside echocardiography, to
demonstrate any regional wall motion
abnormalities, and cardiac troponin mea-
surement can be used where angiography is
not available.
In case of doubts, thrombolysis should not be withheld, as it remains largely safe with life
saving effects.
M Egred
W L Morrison
m.egred@ctc.nhs.uk
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